2024-515925-27-00
Not yet recruiting
Phase 3
Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney transplant patients - CYTOPREV
Centre Hospitalier Universitaire Rouen2 sites in 1 country144 target enrollmentStarted: August 13, 2024Last updated:
Overview
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 144
- Locations
- 2
- Primary Endpoint
- Proportion of patients with CMV infection within 6 months of transplantation.
Overview
Brief Summary
Demonstrate, in CMV+ transplant patients, the effectiveness of an immuno-guided preventive strategy compared to the universal prophylactic strategy, in terms of CMV infection in the 6 months following kidney transplantation.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •18 years ≤ Age ≤ 75 years
- •Renal transplant patient for 1 to 12 days
- •CMV seropositivity on the day of transplantation: IgG threshold =6 AU/mL CMIA CMV IgG, Architect i4000 (Abbott)) (Serology performed on D0, before the transplant)
- •Non-depleting inducing immunosuppressive treatment (Basiliximab) (implementation before the transplant)
- •Affiliation to a social security scheme
- •Patient having read and understood the information letter and signed
- •For women: - Woman of childbearing potential using effective contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) for at least 1 month and a negative β-HCG blood pregnancy test at inclusion, throughout the duration of study treatment and for at least 30 days after stopping study treatment. - Postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months before the inclusion visit) - Surgically sterile woman (absence of ovary and/or uterus)
- •Pour les hommes : - Stérilité chirurgicale, ou - Contraception mécanique (préservatif) pendant toute la durée du traitement à l’étude et pendant au moins 90 jours après la fin du traitement à l’étude, ou - Avec une partenaire en âge de procréer prenant une contraception efficace (Cf. CTFG) (oestro-progestatifs ou dispositif intra-utérin ou ligature de trompes) depuis au moins 1 mois à l’inclusion, pendant toute la durée du traitement à l’étude et pendant au moins 90 jours après l’arrêt du traitement, ou - Avec une partenaire ménopausée : diagnostic de confirmation (aménorrhée non médicalement induite depuis au moins 12 mois avant la visite d’inclusion), ou - Avec une partenaire chirurgicalement stérile (absence d’ovaire et/ou d’utérus).
Exclusion Criteria
- •Age < 18 or > 75
- •Active CMV infection (detectable CMV DNAemia - peripheral CMV DNAemia ≥ 305 IU/mL)
- •Patient with hypersensitivity to valganciclovir, ganciclovir, aciclovir or valaciclovir or to any of the excipients
- •Lympho-depleting inducing immunosuppressive treatment (antithymoglobulins)
- •Neutropenia (neutrophils < 500/mm3) or thrombocytopenia (platelets < 25,000/mm3) or anemia (hemoglobin < 8g/dl) identified on routine care samples taken on the day of inclusion
- •Pregnant or parturient or breast-feeding woman or absence of proven contraception
- •Person deprived of liberty by an administrative or judicial decision or person placed under legal safeguard / sub-tutorship or curatorship
- •History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for their participation in the protocol or preventing them from giving their informed consent
- •Person participating in another interventional trial (Medicinal product)
Outcomes
Primary Outcomes
Proportion of patients with CMV infection within 6 months of transplantation.
Proportion of patients with CMV infection within 6 months of transplantation.
Secondary Outcomes
- Proportion of patients requiring the use of curative antiviral treatment within 6 months after transplantation
- Proportion of patients with CMV disease within 6 months of transplantation
- Proportion of patients with CMV infection (CMV DNAemia ≥ 305 IU/mL (= 2.3 log IU/mL), CMV infection (CMV DNAemia ≥ 4 log IU/mL requiring curative treatment or CMV disease within the first year following transplant
- Number of CMV-specific T lymphocytes (IE-1 and pp65) at W+15
- Number of CMV-specific T lymphocytes (IE-1 and pp65) at W+28
- CMV serological status of the donor (D+/R+ versus D-/R+)
- Incremental cost-effectiveness ratio will be calculated for the period from randomization to the visit at S+28 post-transplantation for the experimental group (Arm ) compared to the comparator group (Arm ) with the average costs and efficacies for each strategy. The incremental cost-effectiveness ratio will be presented as additional cost per CMV infection avoided.
Investigators
David MALLET
Scientific
Centre Hospitalier Universitaire Rouen
Study Sites (2)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Primary prevention of type 1 diabetes in young children at high risk for type 1 diabetes using intranasal insuliRisk for type 1 diabetesTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2015-003379-31-DETechnische Universität München, Fakultät für Medizin38
Completed
Phase 3
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.Rotavirus InfectionsRotavirus VaccinesNCT05037435Limited Liability Company Pharm Aid40
Recruiting
Not Applicable
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
Completed
Not Applicable
Clinical efficacy of prevention against infectious complication after transrectal prostate biopsy and molecular and microbiological analysis of rectal Escherichia coli with quinolone-resistancesuspected prostate cancerJPRN-UMIN000009755Department of Urology, Sapporo Medical University School of Medicine1,000
Not yet recruiting
Phase 2
A study of the effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) for patients with esophageal cancer who receive DCF therapy.esophageal cancerJPRN-UMIN000015561Osaka University School of Medicine Gastroenterological Surgery23